ArriVent BioPharma (AVBP) Return on Capital Employed (2024 - 2026)
ArriVent BioPharma (AVBP) reported Return on Capital Employed of 49.61% for Q1 2026, up 1084.0% on a YoY basis from 4.19% in Q1 2025, and up 15.08% sequentially from 58.42% in Q4 2025.
ArriVent BioPharma (AVBP) Return on Capital Employed (2024 - 2026) Analysis & Trends
ArriVent BioPharma (AVBP) has 3 years of Return on Capital Employed data on file, last reported at 49.61% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed rose 1084.0% year-over-year to 49.61%; the trailing twelve-month figure through Mar 2026 stood at 49.61% (up 1084.0% YoY), and the FY2025 full-year result was 63.84%, down 1709.0% from the prior year.
- Return on Capital Employed improved to 49.61% in Q1 2026, from 58.42% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 28.15% in Q2 2024 to a low of 66.56% in Q2 2025.
- A 3-year average of 47.27% and a median of 49.61% in 2026 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed slumped 3841 bps in 2025 and jumped 1084 bps in 2026, its largest moves.
- Tracing AVBP's Return on Capital Employed over 3 years: stood at 35.38% in 2024, then slumped by 65 bps to 58.42% in 2025, then gained by 15 bps to 49.61% in 2026.
- Business Quant data shows AVBP's Return on Capital Employed at 49.61% in Q1 2026, 58.42% in Q4 2025, and 58.75% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | ArriVent BioPharma | 1.42 Bn | 1.42 Bn | - | -49.61% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -49.61% |
| Dec 31, 2025 | -58.42% |
| Sep 30, 2025 | -58.75% |
| Jun 30, 2025 | -66.56% |
| Mar 31, 2025 | -60.45% |
| Dec 31, 2024 | -35.38% |
| Sep 30, 2024 | -32.81% |
| Jun 30, 2024 | -28.15% |
| Mar 31, 2024 | -35.28% |